Actinium Pharmaceuticals, Inc.
AMEX: ATNM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sandesh C. Seth
- Employees
- 31
- Headquarters
- New York City, United States
- IPO year
- 2012
- Market cap
- $32.3M
- Website
- https://www.actiniumpharma.com
Loading ATNM…
Loading profile data…Frequently asked questions about ATNM
What does Actinium Pharmaceuticals, Inc. (ATNM) do?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinica...
Where does ATNM trade?
Actinium Pharmaceuticals, Inc. (ATNM) trades on the New York Stock Exchange American.
What sector is ATNM in?
Actinium Pharmaceuticals, Inc. (ATNM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Actinium Pharmaceuticals, Inc.?
Sandesh C. Seth is the chief executive officer of Actinium Pharmaceuticals, Inc. (ATNM).
Where is Actinium Pharmaceuticals, Inc. headquartered?
Actinium Pharmaceuticals, Inc. is headquartered in United States.
Does ATNM pay a dividend?
Actinium Pharmaceuticals, Inc. (ATNM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATNM go public?
Actinium Pharmaceuticals, Inc. (ATNM) completed its initial public offering in 2012.